Table 2

Percent of subjects with improvement in the Boolean* and SDAI remission components, radiographic non-progression and remission at week 52 by patient group and treatment

ETN+MTXMTX
VERAERAp ValueVERAERAp Value
≤1 Swollen joint74.670.10.5059.245.90.11
≤1 Tender joint77.8§65.00.0744.9§46.60.83
CRP ≤1 mg/dl87.1§85.00.7069.6§67.60.80
PtGA ≤128.631.80.6414.323.60.17
PhGA ≤169.8§55.40.0540.8§38.50.78
ΔmTSS ≤0.580.679.50.8573.950.00.01
By treatmentETN+MTXMTX alonep Value
≤1 Swollen joint71.449.2<0.01
DAS28 remission**54.132.5<0.01
SDAI remission††25.312.2<0.01
Boolean remission‡‡24.911.1<0.01
  • * Boolean components include ≤1 swollen joint, ≤1 tender joint, CRP ≤1mg/dl and PtGA ≤1.

  • SDAI components include swollen joint count, tender joint count, PtGA, PhGA and CRP (data not available for calculating SDAI for all subjects).

  • p Value for disease duration effect.

  • § p<0.05 For treatment effect within VERA subjects.

  • p<0.05 For treatment effect within ERA subjects.

  • ** DAS28 remission defined as score of <2.6.

  • †† SDAI remission defined as score of ≤3.3 (data not available for calculating SDAI for all subjects).

  • ‡‡ Boolean remission defined as subjects who simultaneously achieve ≤1 swollen joint, ≤1 tender joint, CRP ≤1 mg/dl and PtGA ≤1.

  • CRP, C reactive protein; DAS, disease activity score; ERA, early rheumatoid arthritis (4 months to 2 years); ETN, etanercept; mTSS, modified total Sharp score; MTX, methotrexate; PhGA, physician global assessment; PtGA, patient global assessment; SDAI, simplified disease activity index; VERA, very early rheumatoid arthritis (≤4 months).